ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MIRM vs JNJ // GROSS PROFIT MARGIN

Mirum Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MIRM 2 — JNJ 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MIRM JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -3.90% 25.50% -29.40 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield 0.98% 2.97% -1.99 JNJ /fcf-yield <GO>
Operating Margin -4.20% 34.70% -38.90 JNJ /operating-margins <GO>
Net Profit Margin -4.50% 28.50% -33.00 JNJ /net-margins <GO>
Revenue Growth (YoY) 54.70% 6.00% +48.70 MIRM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.29 5.59 +0.70 MIRM /balance-sheet <GO>
Piotroski F-Score Quality 8/9 8/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.4 59.1 -10.70 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.99 1.08 -0.09 JNJ /macro-sensitivity <GO>
Forward P/E Multiple 32.0x 23.0x +9.00 JNJ /forward-pe <GO>
Enterprise Scale & Market Cap $5.52B $657.68B -$652.16B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MIRM REV JNJ REV MIRM GROSS % JNJ GROSS % MIRM FCF JNJ FCF
FY 2025 $521.3M $94.19B — 67.9% $54.9M $19.70B
FY 2024 $336.9M $88.82B — 69.1% $9.3M $19.84B
FY 2023 $186.4M $85.16B — — -$79.3M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
JNJ // BETA 1.08